BridgeBio Oncology Therapeutics Inc (BBOT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.30-0.86%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · BBOT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -88.5% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 73.5% |
Growth built into the price is above our model estimate.
The price assumes 162.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
BBOT — director transition
Dated 2026-11-05
Chief Medical and Development Officer — Yong Ben, M.D., M.B.A.: The Chief Medical and Development Officer is resigning, which is a genuine departure of a senior officer, but the notice period and lack of stated disagreement suggest an orderly exit rather than a crisis.
Why it matters: The available event note flags an earnings miss but gives no details. The next report can clarify its impact.
Watch forThe November 11 report clearly explains the August miss. It confirms 2026 study timelines remain on track.
Also watch forThe report links the miss to weaker cash runway or delays the Q4 2026 or mid-2027 data updates.
Why it matters: More patient data will test the early response rate in patients whose cancer progressed after a KRAS G12C drug.
Watch forThe expanded study reports an ORR near or above 53% across doses. Safety remains manageable.
Also watch forThe expanded study reports an ORR below 53%, serious safety concerns, or a delay past mid-2027.
Why it matters: The update can show if these drug candidates work well enough for later tests with other drugs.
Watch forThe Q4 update reports tumor response or disease control in a study of either drug alone.
Also watch forThe update reports no tumor responses, weak disease control, or a delay beyond Q4 2026.
Why it matters: BBOT reported a $344.1 million cash balance and said it could fund work into 2028. Lower cash could limit its studies.
Worry ifA later company update confirms the cash balance and runway still extend into 2028.
Less concerning ifA company update says cash no longer funds operations into 2028, or shows a sharp drop from $344.1 million.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$234 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $753 loss on $10,000 · 7.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,325 loss on $10,000 · 83.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.